A patient who took 90 mg of Vyvanse (lisdexamfetamine) this morning cannot sleep; what medication should be given to promote sleep?

Management of Stimulant-Induced Insomnia

For a patient who took 90 mg of Vyvanse this morning and cannot sleep, start with a short-acting benzodiazepine receptor agonist (BzRA) such as zolpidem 10 mg or zaleplon 10 mg at bedtime, or alternatively use low-dose trazodone 50 mg if there are concerns about BzRA use.

Clinical Context and Rationale

This is stimulant-induced insomnia from lisdexamfetamine (Vyvanse), which has a duration of action extending 10-14 hours. The FDA label explicitly warns to "avoid afternoon doses because of the potential for insomnia" 1. Insomnia is a well-documented adverse effect of stimulant medications, with delayed sleep onset being the most common sleep disturbance 2, 3, 4.

First-Line Pharmacologic Options

Short-Acting BzRAs (Preferred for Sleep Onset)

Zaleplon 10 mg is particularly appropriate here because:

• Very short half-life, specifically designed for sleep onset insomnia 5
• Can be used even if only 4 hours remain for sleep 5
• Minimal residual morning sedation 5
• Dose: 10 mg at bedtime (maximum 20 mg) 5

Zolpidem 10 mg is an alternative option:

• Effective for sleep onset insomnia 5, 6
• Short to intermediate-acting 5
• Important caveat: FDA reduced recommended doses to 5 mg for immediate-release in women and elderly due to next-morning impairment risk 7
• Dose: 5-10 mg at bedtime depending on patient characteristics 5

Alternative: Low-Dose Sedating Antidepressant

Trazodone 50 mg is reasonable if:

• Patient has substance use concerns (BzRAs are Schedule IV controlled substances) 5
• Patient is elderly (benzodiazepines should be avoided in older patients due to cognitive impairment risk) 7
• However, the 2017 AASM guideline suggests against using trazodone for insomnia due to weak efficacy evidence 6, and the 2020 VA/DoD guideline advises against it based on low-quality evidence 8
• Dose: 50 mg at bedtime 7

Options to Avoid

Do NOT use:

• Benzodiazepines (lorazepam, clonazepam): While effective, they carry higher risks of dependency, falls, cognitive impairment, and are specifically advised against in current guidelines 8
• Antihistamines (diphenhydramine): Not recommended due to antimuscarinic effects, tolerance develops after 3-4 days, and strong recommendation to avoid in older adults per Beers Criteria 8, 6
• Antipsychotics (quetiapine): Insufficient evidence for insomnia, significant harm potential including increased mortality risk in elderly 8

Dosing Considerations

• Elderly or debilitated patients: Use lower doses (zaleplon 5 mg, zolpidem 5 mg) 5
• Hepatic impairment: Reduce doses (zaleplon 5 mg, zolpidem 5 mg) 5
• Administer on empty stomach to maximize effectiveness 5
• Allow adequate time for sleep (7-8 hours) before activities requiring alertness 5

Important Safety Warnings

All BzRAs carry FDA warnings about:

• Complex sleep behaviors (sleepwalking, sleep driving, sleep eating) 5, 8
• Next-morning impairment affecting driving ability 7
• Avoid combining with alcohol or other CNS depressants 5
• Use lowest effective dose for shortest duration 8

Long-Term Management Strategy

This is an acute intervention. For ongoing management:

1. Reassess Vyvanse dosing and timing: The 90 mg dose is at the maximum recommended level 1. Consider whether this dose is necessary or if timing adjustment could help.

2. Behavioral interventions should be primary: Stimulus control, sleep hygiene, and sleep restriction are guideline-recommended first-line approaches 5, 9

3. If chronic insomnia develops: Consider cognitive behavioral therapy for insomnia (CBT-I), which is the preferred long-term treatment 9

4. Melatonin may be considered for chronic management, though evidence is limited 6, 2. It works through circadian rhythm resynchronization rather than sedation 10.

Clinical Pearls

• Most stimulant-related sleep effects are mild and improve over time 2, 4
• Small studies show inconsistent effects of stimulant medication on sleep parameters 4
• The goal is acute symptom relief tonight while addressing the underlying cause (stimulant timing/dosing) for future prevention
• Document this adverse effect and counsel patient about taking Vyvanse earlier in the morning to minimize evening insomnia 1